Editorial Board About Us

Naoki Yoshimura

All articles from this author are listed below.

Volume 3, Number 3 Meeting Reviews

Interstitial Cystitis and Bladder Research: Progress and Future Directions

NIDDK and ICA International Research Symposium

Naoki Yoshimura Michael B Chancellor

Gene therapy Antiproliferative factor (APF)Epidermal growth factor (EGF)Heparin-binding epidermal growth factor-like growth factor (HB-EGF)Herpes simplex virus Interstitial cystitis (IC)IC, in men IC, in children Intravesical peppers Substance P (SP)

Volume 5, Supplement 8 Supplement

Neurophysiology of Lower Urinary Tract Infection and Dysfunction

Naoki Yoshimura Michael B Chancellor

Overactive bladder Capsaicin Oxybutynin Serotonin Muscarinic receptors

Volume 6, Supplement 3 Supplement

Neurophysiology of Stress Urinary Incontinence

Naoki Yoshimura Michael B Chancellor

Stress urinary incontinence Neurourology Lower urinary tract

Volume 6, Supplement 1 Supplement

Differential Diagnosis and Treatment of Impaired Bladder Emptying

Naoki Yoshimura Michael B Chancellor

Urethra Bladder Ultrasound Urinary retention Bethanechol

Volume 9, Number 3 Review Articles

Advances in the Understanding of Stress Urinary Incontinence and the Promise of Stem-Cell Therapy

Treatment Update

Naoki Yoshimura Akira Furuta Lesley K Carr Michael B Chancellor

The middle urethra and external urethral sphincter are the focus in management of stress urinary incontinence, and recent cellular-therapy research suggests a new paradigm in treatment. Cell-based therapies are most often described as using autologous multipotent stem cells procured from bone marrow in procedures that may be painful, require anesthesia, and yield low numbers of mesenchymal stem cells upon processing. In contrast, muscleand adipose-derived stem cells can be obtained easily in large quantities under local anesthesia. Instead of lifting the urethra with a sling or bulking up the urethral sphincter with collagen, we now have the potential to restore function with the use of autologous stem cells. [Rev Urol. 2007;9(3):106-112]

Urinary incontinence Urethral sphincter Muscle-derived stem cells

Volume 11, Number 2 Meeting Reviews

Best of the 2009 AUA Annual Meeting

Highlights From the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL

Michael K Brawer Naoki Yoshimura Arie S Belldegrun B Shuch F Pouliot Ellen Shapiro Alan W Partin Michael B Chancellor Dean G Assimos Stacy Loeb J Curtis Nickel Claus G Roehrborn

Prostate cancer screening Obesity Benign prostatic hyperplasia Lower urinary tract symptoms Vesicoureteral reflux Nephrolithiasis Stress urinary incontinence Inflammation Silodosin Hormonal therapy Tumor markers TMPRSS2ERG 4-Kallikrein panel Botulinum toxin type A Male voiding dysfunction Benign prostatic specific antigen Roux-en-Y gastric bypass surgery Genitourinary pain index UPOINT clinical phenotype system Nephron-sparing surgery Watchful waiting Laparoscopy for adrenal cortical carcinoma Partial adrenalectomy Urethral trauma Pediatric urethral stricture Enteric urologic surgery

Volume 15, Number 1 Review Articles

The Other Bladder Syndrome: Underactive Bladder

Management Review

Minoru Miyazato Naoki Yoshimura Michael B Chancellor

Detrusor underactivity, or underactive bladder (UAB), is defined as a contraction of reduced strength and/or duration resulting in prolonged bladder emptying and/or a failure to achieve complete bladder emptying within a normal time span. UAB can be observed in many neurologic conditions and myogenic failure. Diabetic cystopathy is the most important and inevitable disease developing from UAB, and can occur silently and early in the disease course. Careful neurologic and urodynamic examinations are necessary for the diagnosis of UAB. Proper management is focused on prevention of upper tract damage, avoidance of overdistension, and reduction of residual urine. Scheduled voiding, double voiding, al-blockers, and intermittent self-catheterization are the typical conservative treatment options. Sacral nerve stimulation may be an effective treatment option for UAB. New concepts such as stem cell therapy and neurotrophic gene therapy are being explored. Other new agents for UAB that act on prostaglandin E2 and EP2 receptors are currently under development. The pharmaceutical and biotechnology industries that have a pipeline in urology and women’s health may want to consider UAB as a potential target condition. Scientific counsel and review of the current pharmaceutical portfolio may uncover agents, including those in other therapeutic fields, that may benefit the management of UAB. [Rev Urol. 2013;15(1):11-22 doi: 10.3909/riu0558] © 2013 MedReviews®, LLC

Underactive bladder Overactive bladder Detrusor overactivity Diabetic cystopathy